Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ClinicalTrials.gov Postings Should Include Studies For All Diseases – PhRMA

This article was originally published in The Pink Sheet Daily

Executive Summary

PhRMA revises earlier policy, which advised companies to post trials only for “serious and life-threatening” conditions, as mandated by FDAMA. Policy change comes as international trade associations adopt universal principles on clinical trial disclosure.
Advertisement

Related Content

Lilly To Begin Posting All Phase II-IV Trials To ClinicalTrials.gov
Lilly To Begin Posting All Phase II-IV Trials To ClinicalTrials.gov
PhRMA Clinical Trial Registry Will Be Launched Oct. 1
PhRMA Clinical Trial Registry Will Be Launched Oct. 1

Topics

Advertisement
UsernamePublicRestriction

Register

PS061045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel